Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | NPC1 | O15118 | 1/20 | 0.77 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.69 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.69 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.69 |
| ▸ | CDK1 | P06493 | 1/20 | 0.69 |
| ▸ | CSF1R | P07333 | 1/20 | 0.69 |
| ▸ | PRKACA | P17612 | 1/20 | 0.69 |
| ▸ | FLT1 | P17948 | 1/20 | 0.69 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.69 |
| ▸ | CDK2 | P24941 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | AKT1 | P31749 | 1/20 | 0.69 |
| ▸ | FLT4 | P35916 | 1/20 | 0.69 |
| ▸ | KDR | P35968 | 1/20 | 0.69 |
| ▸ | FLT3 | P36888 | 1/20 | 0.69 |
| ▸ | GSK3A | P49840 | 1/20 | 0.69 |
| ▸ | GSK3B | P49841 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5968858 | 1.00 | ALDH1A1 (0.77) | ALDH1A1SMN1; SMN2LMNANPC1ROCK2 | |
| SCHEMBL1101522 | 1.00 | ALDH1A1 (0.77) | ALDH1A1SMN1; SMN2LMNANPC1ROCK2 | |
| SCHEMBL28651689 | 0.89 | SMN1; SMN2 (0.73) | ALDH1A1SMN1; SMN2LMNANPC1ROCK2 | |
| SCHEMBL9318785 | 0.89 | SMN1; SMN2 (0.73) | ALDH1A1SMN1; SMN2LMNANPC1ROCK2 | |
| SCHEMBL17369057 | 0.89 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2LMNANPC1ROCK2 | |
| SCHEMBL29135907 | 0.89 | SMN1; SMN2 (0.73) | ALDH1A1SMN1; SMN2LMNANPC1ROCK2 | |
| SCHEMBL3755011 | 0.89 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2LMNANPC1ROCK2 | |
| SCHEMBL3756762 | 0.89 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2LMNANPC1ROCK2 | |
| SCHEMBL2919150 | 0.89 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2LMNANPC1ROCK2 | |
| SCHEMBL13947536 | 0.89 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2LMNANPC1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190177707-A1 | CARBOXYESTERASE POLYPEPTIDES FOR AMIDE COUPLING | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2019-06-13 | — | — | US | claimed |
| EP-3303291-A1 | ROR GAMMA (ROR ) MODULATORS | Lead Pharma Holding B.V. (NL) | 2018-04-11 | — | — | EP | claimed |
| WO-2016193452-A1 | ROR GAMMA (RORγ) MODULATORS | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2016-12-08 | — | — | WO | claimed |
| US-9096768-B2 | Curable phase change ink compositions | XEROX CORPORATION (US) | 2015-08-04 | — | — | US | claimed |
| US-12286653-B2 | Carboxyesterase polypeptides for amide coupling | CODEXIS, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| CN-119684070-A | HFIP power assisting C (sp3) Direct methylation method of-H bond and application thereof | 西南大学 | 2025-03-25 | — | — | CN | disclosed |
| US-20240353322-A1 | COMBINED DETERMINATION OF THE CONCENTRATION AND ENANTIOMERIC COMPOSITION OF CHIRAL COMPOUNDS USING SINGLE CHIROPTICAL ASSAY | GEORGETOWN UNIVERSITY | 2024-10-24 | — | — | US | disclosed |
| US-20240261296-A1 | THERAPEUTIC MODALITIES FOR INHIBITING PANCREATIC BETA CELL IMPAIRMENT AND TREATING DIABETES | Hadasit Medical Research Serices & Development Ltd. (IL) | 2024-08-08 | — | — | US | disclosed |
| EP-4319734-A2 | PROSTAGLANDIN RECEPTOR 3 (EP3) ANTAGONISTS FOR USE IN THE TREATMENT OF DIABETES | Hadasit Medical Research Services&Development Ltd. (IL) | 2024-02-14 | — | — | EP | disclosed |
| EP-3489215-B1 | PROCESS FOR PRODUCING ORGANIC COMPOUND | KANEKA CORP (JP) | 2023-12-20 | — | — | EP | disclosed |
| EP-3475308-B1 | USE OF 2,4,6-SUBSTITUTED-1,3,5-TRIAZINES AND DERIVATIVE THEREOF AS CONDENSATION, CROSS-LINKING, TANNING, GRAFTING AND CURING AGENTS | CROSSING S R L (IT) | 2023-01-25 | — | — | EP | disclosed |
| WO-2022215072-A2 | THERAPEUTIC MODALITIES FOR INHIBITING PANCREATIC BETA CELL IMPAIRMENT AND TREATING DIABETES | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD. (IL) | 2022-10-13 | — | — | WO | disclosed |
| EP-1049691-A1 | SUBSTITUTED 5-(2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL) CYCLOPENTENOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999037639-A1 | SUBSTITUTED 5-(2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL) CYCLOPENTENOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-07-29 | — | — | WO | disclosed |
| EP-0270095-B1 | PACKING MATERIAL FOR LIQUID CHROMATOGRAPHY | Tosoh Corporation (JP) | 1991-11-13 | — | — | EP | disclosed |
| US-4830921-A | RESOLUTION OF RACEMIC MIXTURES | TOSOH CORPORATION (JP) | 1989-05-16 | — | — | US | disclosed |
| EP-0158526-B1 | IMPROVEMENTS IN OR RELATING TO ANTICONVULSANT AGENTS | ELI LILLY AND COMPANY (US) | 1987-07-08 | — | — | EP | disclosed |
| EP-0078845-A4 | ANTI-CONVULSANT. | CLARK CHARLES RANDALL | 1983-09-02 | — | — | EP | disclosed |
| EP-0078845-A1 | ANTI-CONVULSANT. | CLARK CHARLES RANDALL | 1983-05-18 | — | — | EP | disclosed |
| WO-1982004046-A1 | ANTI-CONVULSANT | CLARK CHARLES RANDALL | 1982-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240261296-A1 | THERAPEUTIC MODALITIES FOR INHIBITING PANCREATIC BETA CELL IMPAIRMENT AND TREATING DIABETES | IAPP, PTGER3, GPR119 | ALDH1A1 2596/4885SMN1; SMN2 1885/4885LMNA 2133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.